Guidelines for the delivery of Directly Observed Therapy in the community to persons with TB disease

<table>
<thead>
<tr>
<th>Document reference number</th>
<th>Version 1.0 February 2013</th>
<th>Document developed by</th>
<th>TB DOT subgroup of HSE TB Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision number</td>
<td>1.0</td>
<td>Document approved by</td>
<td>Assistant National Director of ISD-Health Protection</td>
</tr>
<tr>
<td>Approval date</td>
<td>22/11/2012</td>
<td>Responsibility for implementation</td>
<td></td>
</tr>
<tr>
<td>Revision date</td>
<td>November 2015</td>
<td>Responsibility for review and audit</td>
<td></td>
</tr>
</tbody>
</table>
Contents
1. Glossary of Terms and Definitions ................................................................................. 4
2. Background ..................................................................................................................... 5
  2.1 What is DOT .............................................................................................................. 5
  2.2 Rationale for DOT .................................................................................................... 5
  2.3 Universal versus Selective DOT ............................................................................. 5
  2.4 Target Groups for Selective DOT ............................................................................ 6
  2.5 Promoting adherence ............................................................................................... 6
  2.6 Advantages of DOT ................................................................................................. 6
  2.7 Perceived disadvantages of DOT ........................................................................... 7
  2.8 How can a Key Worker/DOT provider build rapport and trust? ......................... 7
  2.9 Key Worker/DOT provider ...................................................................................... 7
3. Guideline Statement ...................................................................................................... 8
4. Purpose .......................................................................................................................... 8
5. Scope ............................................................................................................................. 8
6. Roles and Responsibilities .............................................................................................. 9
  6.1 Referring physician ................................................................................................. 9
  6.2 Director of Public Health Nursing ........................................................................ 9
  6.3 Assistant Director of Public Health Nursing ........................................................ 10
  6.4 Staff supervising DOT administration ................................................................ 10
  6.5 Public Health Department ..................................................................................... 11
7. Management of DOT process ....................................................................................... 12
  7.1 Referral Pathway .................................................................................................... 12
  7.2 Procedure ................................................................................................................ 12
  7.3 Documentation ....................................................................................................... 13
8. Revision and Audit ........................................................................................................ 13
9. Production/Consultation Trail ...................................................................................... 14
10. References/Bibliography ............................................................................................ 15
11. Suggested Reading ..................................................................................................... 15
12. List of Appendices: .................................................................................................... 16
    Appendix I: Doses of Primary Medications used in the treatment of TB (p1/2) .......... 17
    Appendix I: Doses of Primary Medications used in the treatment of TB (p2/2) .......... 18
    Appendix III: Degree of infectiousness of the patient ............................................. 20
Appendix IV: Letter to Regional Director of Operations from Assistant National Director of Health Protection re DOT ................................................................................................................................. 21
Appendix V: Membership of Working Group .................................................................................................................. 22
Appendix VI: List of Stakeholders Involved in Peer Review ............................................................................................ 23
Appendix VII: DOT Recording Form .................................................................................................................................. 24
1. Glossary of Terms and Definitions

**Active Tuberculosis (TB)** - Human tuberculosis is caused by infection with bacteria of the Mycobacterium tuberculosis complex (*M. tuberculosis, M. bovis, M. africanum*). The organism may infect any part of the body. However, the majority of cases involve the respiratory system (National TB Advisory Committee, 2010). Active TB is characterised by symptoms of weight loss, cough, night sweats and fever.

**Bacille Calmette-Guerin (BCG) vaccination** - vaccine derived by in-vitro attenuation of the bovine tubercle bacillus between the years 1908 and 1918 in France. The clinical efficacy of a vaccine is measured in terms of the percentage reduction in disease among vaccinated individuals that is attributed to vaccination i.e. the proportion of those vaccinated who gain protective immunity from the vaccine. BCG vaccine does not give 100% protection but it does protect against the more serious forms of the disease e.g. TB meningitis and miliary tuberculosis with protection lasting approximately 15 years (National TB Advisory Committee, 2010).

**DOT** - Direct observed therapy. DOT refers to the supervision of a patient taking a correctly prescribed dose of TB medication and swallowing the medication.

**Key Worker /DOT Provider** - The key worker will be actively involved in the supervision of DOT and should actively monitor and ensure adherence (National TB Advisory Committee, 2010). Measures should be mutually acceptable to the patient and the key worker who is acceptable and accountable to the patient and to the health system.

**Extensively Drug Resistant Tuberculosis (XDR-TB)** - resistance to at least isoniazid and rifampicin (i.e. MDR-TB), plus resistance to any fluoroquinolone, and any one of the second line anti-TB injectable drugs (capreomycin, amikacin or kanamycin). (National TB Advisory Committee, 2010)

**Latent TB infection** - A person with latent TB infection (LTBI) usually has a positive tuberculin skin test (mantoux /TST) or interferon gamma (IGRA) test but has no physical findings of TB disease and the chest X-ray is normal or only reveals evidence of healed infection e.g. granulomas or calcification in the lung, hilar nodes or both. Persons with LTBI are asymptomatic and are not infectious (National TB Advisory Committee, 2010).

**MOH**
Medical Officer of Health

**Multi-Drug Resistant Tuberculosis (MDR-TB)**
MDR-TB is a specific form of TB which is resistant to at least isoniazid and rifampicin, two of the main first line drugs used in the treatment of TB. MDR-TB therefore is much more difficult to treat, takes longer to treat with second line drugs (which are more expensive and have more side-effects) and the outcome is not always successful. Treatment is directed by a consultant respiratory physician/consultant in infectious disease with appropriate training in the management and treatment of TB and should be in line with the International Standards for TB Care (i.e. given for two years). (National TB Advisory Committee, 2010) MDR-TB may require IV infusions in addition to oral medications.
2. **Background**

It is acknowledged that directly observed therapy (DOT) is an internationally proven method recommended by the World Health Organization (WHO) to prevent the spread of tuberculosis in the community by providing infected persons with the support necessary for effective treatment to ensure a rapid and lasting cure.

2.1 **What is DOT**

Direct Observation of Therapy (DOT) means a trained healthcare worker or other designated individual (excluding family member and friends) observes the patient diagnosed with TB swallow the prescribed medication over the course of their treatment. This ensures that a patient diagnosed with TB takes the correct drugs and correct dose at the correct times. It is important that DOT is acceptable to the patient and to ensure that key workers are aware of their accountability and adhere to practice in relation to confidentiality.

2.2 **Rationale for DOT**

It can be difficult to predict who will take medications as directed and who will not. Persons from all backgrounds, gender and ethnicities and of all age groups can have problems taking medications directly. Each patient with a diagnosis of TB should be assessed to determine the likelihood of adherence with treatment. DOT should be prescribed for all patients with suspected or confirmed TB who demonstrate that they may be incapable, unreliable or unwilling to take TB drugs. DOT also reduces the risk of drug resistance, relapse and reactivation of TB disease and mortality from TB. In addition, it also helps prevent TB spreading to others. DOT helps identify problems which might interrupt treatment and allows the healthcare worker (HCW) to monitor the patient regularly for side effects and response to anti-tuberculous therapy.

**A multidisciplinary team approach is critical for the effective implementation of DOT**

The benefits of adopting a patient-centred case management approach include:

a) Explaining the rationale for and benefits of DOT to the patient  
b) Ensuring patients attend medical appointments  
c) Providing ongoing patient education  
d) Offering incentives and/or enablers (see p. 6)  
e) Connecting patients with social services or transportation as required

2.3 **Universal versus Selective DOT**

Selective DOT means providing DOT only to clients who are considered to be non-compliant or at high risk of non-compliance or those with a history of resistance to prescribed medications for the treatment of TB (Section 2.4). Universal DOT describes the policy where DOT is used for treating all patients with TB.

Two studies by Ormerod et al show that selective DOT may be used successfully with at least 90% of patients completing treatment (no culture done at the end of treatment) or being cured (negative culture at the end of treatment) (Ormerod et al, 1998; 2002). Based on this evidence, the DOT subgroup has agreed that selective DOT is the best option for Ireland taking into consideration evidence from the aforementioned research and the current resources available for implementation.
2.4 Target Groups for Selective DOT
Clients who are deemed to be non compliant or those who have a history of resistance to prescribed medication for the treatment of TB are referred by a hospital clinician for DOT in the community.

2.4.1 Groups of patients where DOT is the best option include:
- Patients with suspected or proven drug-resistant TB requiring second line treatment e.g. MDR-TB, XDR-TB
- Patients receiving intermittent therapy
- Patients with a history of recurrence or relapse
- Patient with a history of treatment failure
- Persons in correctional facilities (prisons)
- Persons co-infected with HIV (if deemed appropriate following the clinician’s assessment)
- Patients with poor understanding of TB diagnosis or non-acceptance of diagnosis.

2.4.2 Patients at high risk of non-adherence include:
- Homeless or unstably housed persons
- Persons who suffer from substance misuse (alcohol and/or illicit drugs)
- Persons who are unable to take medications due to mental, emotional or physical disability
- Persons with a history of non-adherence

2.5 Promoting adherence

2.5.1 Incentives and Enablers
Incentives and enablers (see definitions below) are tools to assist in the patient’s adherence to TB medication, but DO NOT replace building a therapeutic relationship based on trust and mutual respect.

- An incentive is a reward for desired behaviour
- An enabler is an intervention to assist the patient in completing therapy. It helps patients overcome barriers to treatment.

2.6 Advantages of DOT
- It ensures that the patient is supported to successfully complete the full course of medication
- The patient is closely monitored for side effects of medications and supported to work through the side effects appropriately
- The patient is encouraged and supported to complete regular check-ups e.g. bloods, chest X-ray etc.
- A trust relationship develops between the Key worker/ DOT provider and the patient which reduces fear about TB and its treatment
- Increases the patient’s comfort level so that he/she can ask questions
- Improves the patient’s quality of health care as key worker/DOT provider can be an important link to other community and social resources for the patient
- Reduces the possibility of TB becoming resistant to the medication
2.7 Perceived disadvantages of DOT

- It is time consuming and labour intensive
- Some patients may find that it undermines their independence
- It can be perceived by the patient as demeaning or punitive

It is important to explain the benefits of DOT to each patient and to stress the fact that DOT is not punitive rather it is a way of helping the patient remember to take their medication so that they get better quicker and do not infect others.

2.8 How can a Key Worker/DOT provider build rapport and trust?

- Identify patient concerns
- Protect confidentiality
- Communicate clearly
- Avoid criticising the patient’s behaviour
- Respectfully offer helpful suggestions for change
- Be on time and be consistent
- Be flexible with the time and place for DOT administration
- Adopt and reflect a non-judgemental attitude

2.9 Key Worker/DOT provider

The key worker/DOT provider (nurse or agreed person who is deemed responsible and suitably trained) co-ordinates an agreed process of DOT with the client. Where possible, the key worker/DOT provider is usually a nurse. However, this role can be extended to include other healthcare professionals e.g. pharmacists, GP practice nurse. When the role of key worker/DOT provider is extended to non-healthcare professionals, suitable training and information should be provided.
3. **Guideline Statement**

3.1 The Health Service Executive (HSE) is committed to implementing and promoting measures to ensure the effective and safe management of clients referred for Directly Observed Therapy (DOT).

3.2 It is the policy of the HSE that healthcare professionals who have undertaken required education and training are facilitated to implement and promote the safe and effective management of persons referred for DOT in Primary Care.

4. **Purpose**

This guideline promotes best practice, and must always be used in conjunction with professional judgement. The purpose of this guideline is to:

4.1 Outline the specific requirements indicated in the care of the client referred for the management of tuberculosis utilising DOT safely and within their scope of practice.

4.2 Act as a framework to enable local development and revision of procedures/guidelines by healthcare workers regarding the management of clients referred for Directly Observed Therapy (DOT).

4.3 Provide a standardised framework for healthcare professionals to exercise clinical judgement within the domains of professional accountability.

5. **Scope**

5.1 This guideline applies to all healthcare staff including referring clinicians, senior medical officers (SMO's), specialists in public health medicine, public health nursing staff members and other care workers e.g. GPs, pharmacists, practice nurses involved in the management of DOT.

5.2 Each professional is accountable both legally and professionally for their own practice.
6. **Roles and Responsibilities**

All TB patients are the responsibility of the treating physician until their treatment has been successfully completed.

6.1 **Referring physician**

It is the responsibility of the referring physician to:

- Explain to the patient at the outset the rationale and the need for DOT in their specific case
- Confirm the patient’s willingness to comply with DOT
- Request DOT by completing the referral form and forwarding to the DPHN including prescription(s) (initial and subsequent). A copy of the DOT referral form should be forwarded to the local department of public health.
- Advise when mask-wearing is necessary
- Inform the key worker/DOT provider when there is a change of medication
- Meet with patients who miss DOT doses to discuss problems with adherence
- Call and chair case-conferences as needed for non-compliant patients
- Facilitate hospital admission for patients who are unable/unwilling to comply with DOT and for whom self-medication in the community is deemed inappropriate
- Assist with the education and training of DOT providers.

6.2 **Director of Public Health Nursing**

It is the responsibility of the Director of Public Health Nursing to:

- To ensure that all staff within the Public Health Nursing Services are aware of this policy and that effective communication systems are in place to disseminate this policy document
- To provide the necessary resources and supports to ensure adherence to the policy.
- To ensure that appropriate personal protective equipment (PPE) is available as required by staff undertaking DOT.
- To have robust governance structures in place to monitor and audit practice and ensure patient safety
- To ensure systems are in place, to facilitate education and training with regard to the management of DOT and use of PPE.
• To ensure that risk management policies and procedures are in place for reporting all adverse events, incidents, near misses and adverse drug events

6.3 Assistant Director of Public Health Nursing

It is the responsibility of the Assistant Director of Public Health Nursing to:

• To ensure that all staff within the Public Health Nursing Services involved in the management of clients with DOT are aware of the policy and the significance of adhering to the principles contained within

• To ensure that communication and governance structures are operational at Primary Care level

• To maintain a signature sheet detailing that this policy document is read and understood

• To facilitate evaluation and audit of the policy

6.4 Staff supervising DOT administration

It is the responsibility of the staff supervising DOT administration to:

• To be accountable for their practice; it is the responsibility of each key worker/DOT provider to be familiar with the main pharmacological actions, the usual dose, storage and stability of medication and frequency, route of administration and potential side effects and incompatibilities of the drugs in the management of clients referred for DOT (Appendix 1). This includes appropriate observation of the patient i.e. observing them take their medications.

• Report any difficulties/failures to the treating physician or Public Health

• To ensure they take appropriate steps to develop and maintain competence with regard to the management of clients referred for DOT.

• To ensure that they have read and understand the contents of the policy and have signed to that effect

• To adhere to all related policies, procedures, guidelines and protocols including risk management structures for their area

• To maintain appropriate documentation
6.5 Public Health Department

The role of the Public Health Department is outlined as follows:

**Strategic:**
- To assist in developing, through Regional Collaborative TB Committees, strategies to improve patient adherence
- To participate in the education and training of health professionals/key worker/DOT provider (staff supervising DOT)

**Specific Cases:**
Department of Public Health (Director of Public Health) receives copy of each DOT Referral Request Form (Appendix 2)
- Supportive role (advisory) to supervising key worker/DOT provider if required especially in relation to complex cases
- Alerting the treating consultant physician / treating clinical team if they become aware of concerns re case adherence with DOT
- Collaboration with treating consultant physician in convening DOT case conferences where necessary (chaired by treating consultant physician). It is essential that the DPHN, key worker/ DOT provider and the patient’s GP participate in the case conference and the pharmacist, when appropriate.
- Where a patient on DOT is non-compliant with treatment and resistant to any intervention in the community under Section 38 of the Health Act (1947), the MOH may order the detention and isolation of an infectious person until that person is no longer a probable source of infection. **Note: this legislation is currently under review.**
7. **Management of DOT process**

7.1 **Referral Pathway**

- A referral form is completed by the prescribing clinician. This should be printed to ensure legibility.

- This is forwarded with the prescription (printed to ensure legibility) to the relevant Director of Public Health Nursing (DPHN) and cc’d to the Director of Public Health and to the patient’s GP OR as per local arrangements.

- DPHN forwards the referral form and prescription to the Asst DPHN. The Asst DPHN then contacts the Public Health Specialist by telephone as per local arrangements. The Asst DPHN communicates the referral to the key worker/DOT provider.

- Any changes in medication must be notified in a timely manner by the prescribing hospital clinician to the client and to the DPHN, DPH and attending GP. The DPHN should then advise the key worker/DOT provider.

7.2 **Procedure**

The key worker/DOT provider (nurse or agreed person who is deemed responsible) co-ordinates an agreed process of DOT with the client.

This involves:

- Ensuring that the medication has been obtained by the client prior to the visit
- Confirming the identity of the client at the time of the first visit
- Observing the client’s condition and recording relevant information
- Verifying that the drugs to be taken are as prescribed
- The DOT provider must observe the patient to ensure that the medication has been swallowed
- Document this in clients’ records which includes initialling the time and date that medications were taken
- Report any observed side effects of medications as soon as possible to the referring clinician, GP, DPH and line manager as appropriate

The “five rights” of medication administration should be applied for each patient/service user encounter. These are outlined as follows:

- a) The right medication
- b) The right patient/service user
- c) The right dosage
- d) The right form
- e) The right time
7.2.1 Non-adherence—Where the key worker/DOT provider is unable to access the client for two consecutive appointments and the client is not contactable, the key worker/DOT provider must inform their line manager. The hospital clinician and DPH must also be informed.

7.2.2 Missing Doses

Correction for treatment interruptions depends on the timing of such interruptions i.e. whether they occur in the initiation phase or continuation phase of therapy. The physician in charge of the case will decide and advise on the appropriate course to be followed.

7.2.3 Case Conferences

A case conference is a multidisciplinary review for individual TB cases when difficulties arise with DOT administration. Any difficulties arising with DOT administration should be discussed with the treating physician who may then decide to call a case conference. The treating physician will chair the case conference supported by public health.

7.2.4 Safety and Home Visiting


Document and report all incidents to the DPHN.

7.3 Documentation

The administration of a medicinal product and the patient/service-user response should be accurately documented according to local policy.

8. Revision and Audit

8.1.1 The policy should be reviewed two years for the date effective. The National TB Control Group is responsible for further review. Revision of this document must be considered if new evidence that impacts on this policy emerges in advance of the two year period.

8.1.2 Audit tool: An audit tool which may include feedback from patients/service users should be developed locally to evaluate local processes and procedures.

8.1.3 Services employing DOT should undertake regular audit. The lead on this activity should be by local agreement.
9. Production/Consultation Trail
This document was first drafted and circulated for peer review in July 2012 and was amended following these reviews. Consultation by colleagues was sought and the document further amended accordingly. The authors developed this version of the document on 13th February 2013.
10. References/Bibliography


Directly observed therapy (DOT) for tuberculosis. New Zealand Ministry of Health available at: http://www.moh.govt.nz


11. Suggested Reading


### 12. List of Appendices:

<table>
<thead>
<tr>
<th>Appendix I</th>
<th>Doses of Primary Medications used in the treatment of TB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix II</td>
<td>DOT referral form</td>
</tr>
<tr>
<td>Appendix III</td>
<td>Degree of infectiousness of the patient</td>
</tr>
<tr>
<td>Appendix IV</td>
<td>Letter to Regional Director of Operations from Assistant National Director, ISD-Health Protection re DOT</td>
</tr>
<tr>
<td>Appendix V</td>
<td>Membership of Working Group</td>
</tr>
<tr>
<td>Appendix VI</td>
<td>List of Stakeholders involved in Peer Review Group</td>
</tr>
<tr>
<td>Appendix VII</td>
<td>DOT recording form</td>
</tr>
</tbody>
</table>
## Appendix I: Doses of Primary Medications used in the treatment of TB (p1/2)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mode of action</th>
<th>Route of administration</th>
<th>Daily dose [max]</th>
<th>3 Times a week dose [max]</th>
<th>2 Times a week dose [max]</th>
<th>Major adverse reactions*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td>Bactericidal</td>
<td>Oral/ Intramuscular</td>
<td>Children: 5-10mg/kg Adults: 5mg/kg [300mg]</td>
<td>Children: 20mg/kg Adults: 10mg/kg (range 8-12mg/kg) [900mg]</td>
<td>Children: 20mg/kg Adults: 15mg/kg (range 13-17mg/kg) [900mg]</td>
<td>Hepatic enzyme elevations, hepatitis, rash, peripheral neuropathy, CNS effects, increased phenytoin levels, possible interaction with disulfiram</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>Bactericidal</td>
<td>Oral/ Intravenous</td>
<td>Children: 10-20mg/kg Adults: 600mg (range 8-12mg/kg) [600mg]</td>
<td>Children: 10-20mg/kg Adults: 600mg (range 8-12mg/kg) [600mg]</td>
<td>Children: 10-20mg/kg Adults: 600mg (range 8-12mg/kg) [600mg]</td>
<td>Hepatic enzyme elevations, hepatitis, rash, fever, thrombocytopenia, influenza-like syndrome, reduced levels of many drugs (including methadone, warfarin, hormonal forms of contraception, oral hypoglycaemic agents, theophylline, dapsone, ketoconazole, PIs, and NNRTIs)</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>Bacteriostatic</td>
<td>Oral</td>
<td>Children: 25mg/kg (range 20-30mg/kg) Adults: 25mg/kg (range 20-30mg/kg) [2.0g for adults and children]</td>
<td>Children: 35mg/kg (range 30-40mg/kg) Adults: 35mg/kg (range 30-40mg/kg) [3.0g for adults and children]</td>
<td>Children: 50mg/kg (range 40-60mg/kg) Adults: 50mg/kg (range 40-60mg/kg) [3.5g for adults and children]</td>
<td>Gastrointestinal (GI) upset, hepatotoxicity, hyperuricaemia, gout (rarely), arthralgias, rash</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>Bacteriostatic</td>
<td>Oral</td>
<td>Children: 20mg/kg (range 15-25mg/kg) [1.5g] Adults: 15-25mg/kg [2.0g]</td>
<td>Children: 30mg/kg (range 25-35mg/kg) Adults: 30mg/kg (range 25-35mg/kg) [2.8g]</td>
<td>Children: 40-50mg/kg [2.5g] Adults: 45mg/kg (range 40-50mg/kg) [3.6g]</td>
<td>Decreased red-green colour discrimination, decreased visual acuity, skin rash</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>Bactericidal</td>
<td>Intramuscular/ Intravenous</td>
<td>Children: 15-30mg/kg Adults: 15mg/kg [1.0g]</td>
<td>Children: 15mg/kg Adults: 15mg/kg [1.0g]</td>
<td>Children: 15mg/kg Adults: 15mg/kg [1.0g]</td>
<td>Auditory toxicity, renal toxicity, hypokalaemia, hypomagnesaemia</td>
</tr>
</tbody>
</table>
### Appendix I: Doses of Primary Medications used in the treatment of TB (p2/2)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Recommended regular monitoring</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td>- Monthly clinical evaluation&lt;br&gt;- Liver function tests&lt;sup&gt;1&lt;/sup&gt;</td>
<td>- Vitamin B&lt;sub&gt;6&lt;/sub&gt; (pyridoxine) 10mg/day may decrease peripheral neuritis and CNS effects and should be used in patients who are abusing alcohol, pregnant, breastfeeding infants on isoniazid, malnourished, or who have HIV infection, cancer, chronic renal or liver disease, diabetes, or pre-existing peripheral neuropathy&lt;br&gt;- Aluminium-containing antacids reduce absorption&lt;br&gt;- Drug interactions with several agents</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>- Monthly clinical evaluation&lt;br&gt;- Complete blood cell count including platelets and liver function tests as indicated&lt;sup&gt;2&lt;/sup&gt;</td>
<td>- Orange discolouration may occur in contact lenses and body secretions such as tears and urine&lt;br&gt;- Patients receiving methadone will need their methadone dosage increased, by an average of 50%, to avoid opioid withdrawal&lt;br&gt;- Interaction with many drugs leads to decreased levels of the co-administered drug&lt;br&gt;- May make glucose control more difficult in people with diabetes.&lt;br&gt;- Contraindicated for patients taking most PIs and NNRTIs&lt;br&gt;- Patients should be advised to use barrier contraceptives while on rifampicin</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>- Monthly clinical evaluation&lt;br&gt;- Liver function tests as indicated&lt;sup&gt;1&lt;/sup&gt;</td>
<td>- May complicate management of diabetes mellitus&lt;br&gt;- Hyperuricaemia can be used as indicator of compliance&lt;br&gt;- Treat increased uric acid only if symptomatic&lt;br&gt;- Allopurinol increases level of pyrazinamide by inhibiting xanthine oxidase resulting in failure of allopurinol to lower serum uric acid</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>- Monthly clinical evaluation&lt;br&gt;- Check colour vision and visual acuity monthly</td>
<td>- Optic neuritis may be unilateral; check each eye separately. If possible avoid in children too young to undergo vision testing.&lt;br&gt;- If patient develops visual complaints, refer for prompt ophthalmologic evaluation. May need to discontinue ethambutol while awaiting evaluation.</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>- Monthly clinical evaluation&lt;br&gt;- Audiometry, renal function, electrolytes, including magnesium</td>
<td>- Ultrasound and warm compresses to injection site may reduce pain and induration</td>
</tr>
</tbody>
</table>

<sup>1</sup>World Health Organization (WHO), International Union against TB and Lung Disease (IUATLD), and British Thoracic Society (BTS) recommend 5mg/kg in children; Centers for Disease Control and Prevention (CDC), American Thoracic Society (ATS), Infectious Disease Society of America (IDSA) and the American Academy of Paediatrics (AAP) recommend 10-20mg/kg

<sup>2</sup>WHO, IUATLD, and BTS recommend 10mg/kg in children; CDC/ATS and the AAP recommend 10-20mg/kg

<sup>3</sup>Liver function tests are indicated if baseline is abnormal or patient has risk factors for toxicity

PI= Protease inhibitors  
NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitors
Appendix II: DOT referral form

TO DIRECTOR OF PUBLIC HEALTH NURSING
Fax number: ___________________
Phone number: ___________________

Consultant name
Consultant address line 1
Consultant address line 2
Consultant address line 3
Consultant contact number

REFERRAL REQUEST FOR DIRECTLY OBSERVED THERAPY
TUBERCULOSIS MEDICATION

Name: ___________________  DOB: _____________
Home Address: _______________  Current Address (If different) ___________________
________________________________________  __________________________________
________________________________________  __________________________________
Contact number: ___________________
Hospital: ___________________  Chart number: ___________________
GP name: ___________________  GP contact number: ___________________
Diagnosis: ___________________
Date of commencement of TB therapy

Most recent sputum smear: Date: ___________  Result: _______________
Case currently infectious?  Yes  No
Mask wearing recommended?  Yes  No  If, YES, for how long? ________

Reason(s) for DOT request:
Poor/Non-adherence  Yes  No
MDR-TB  Yes  No
TB relapse  Yes  No
Homeless  Yes  No
Other  Yes  No  Please specify ___________________

Date of next OPD appointment: ___________________

Prescription attached/faxed?  Yes  No

Signed: ___________________________________  Date: _____________
Referring physician

CC Department of Public Health  Yes  No

For further details, please see Appendix 9 (p171) of Guidelines on the Prevention and Control of Tuberculosis in Ireland, 2010. Available at: http://www.hpsc.ie/hpsc/A-Z/VaccinePreventable/TuberculosisTB/Guidance/

1 The above form is a sample form and may need to be adapted for local use
Appendix III: Degree of infectiousness of the patient

Adapted from the *Guidelines on the Prevention and Control of Tuberculosis in Ireland, 2010* (HPSC) (Chapter 6)-available at [www.hpsc.ie](http://www.hpsc.ie)

**Degree of infectiousness**

- It is accepted that a patient who is sputum smear positive or bronchial lavage (BAL) positive is infectious and should be treated as such. However, any patient who has symptoms or signs suggestive of pulmonary TB should be regarded as infectious and treated as such until evidence to the contrary (three properly performed negative sputum smears) have been found.

- Compliant patients, sensitive to appropriate anti-TB treatment are generally deemed non-infectious after 2 weeks of treatment. AFB positive sputum results may continue to be reported due to the persistence of inactive killed organisms which are not infectious.

- A patient who is sputum smear negative can attend a health centre for DOT/DOTS but should be restricted from any contact with immunocompromised patients.

- Some patients who are infectious can remain at home in the household that has already been exposed, as it has been shown that the risk of additional transmission of infection in this setting is extremely low. Exposure duration of less than eight hours is generally considered not to be significant. (National TB Advisory Committee, 2010)

- The use of an FFP2 mask by staff/carers is recommended only when caring for patients with suspected or known infectious TB. FFP3 masks are recommended for the care of patient with suspected or confirmed infectious MDR-TB or XDR-TB.
8th January 2010

To / Regional Director of Operations, HSE.

Re: TB Patients and Directly Observed Therapy (DOT) in the Community

Dear Colleague,

TB is still a major health risk in Ireland and our own indigenous problem has been exacerbated by the arrival of immigrants from areas of much higher incidence. There were 465 cases of TB notified in Ireland in 2006 (crude notification rate 11.0/100,000), slightly higher than the rates reported between 2000 and 2005. Provisional figures for 2007 are in turn slightly higher than 2006 [Report on the Epidemiology of TB in Ireland 2006. HPSC Oct 2008].

Compliance with treatment is central to establishing good cure rates for TB and for preventing the problem of drug resistance. Whenever a treating physician identifies that a TB case is poorly compliant with treatment, or is likely to become so, Directly Observed Therapy (DOT) is generally recommended. DOT is a major element of our national programme of TB control. Suboptimal care of TB patients has implications not only for the patient but also for the wider community. The arrangements for setting up and providing DOT are working in some areas, there have been difficulties in others with regard to the provision of DOT for TB patients in the community.

Various Health Acts and SI’s have indicated that the provision of health care to people with an infectious disease is an universal entitlement.

I would be grateful if you could remind the relevant staff in your area a high priority is given to ensuring that staff are available to provide this service. It is essential that the role of our Public Health Nurse colleagues in TB control be acknowledged and that they be reminded of how crucial their role is in providing DOT in the community.

I would be grateful for your assistance in this. I would also appreciate your confirmation that community provision of DOT will receive ongoing priority. Should you, or Directors of Public Health Nursing, require any clarification on this issue, I am assured that the local Departments of Public Health will be happy to assist.

Yours sincerely,

DR. KEVIN KELLEHER
ASSIST. NATIONAL DIRECTOR FOR POPULATION HEALTH – HEALTH PROTECTION

cc. Each Director of Public Health
### Appendix V: Membership of Working Group

<table>
<thead>
<tr>
<th>Name</th>
<th>Area of Work</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR. Heidi Pelly (Chair)</td>
<td>Specialist in Public Health Medicine, HSE West (Galway, Mayo and Roscommon)</td>
</tr>
<tr>
<td>Dr. Joan O Donnell (secretary from September 2011 to March 2012)</td>
<td>Specialist in Public Health Medicine, HPSC</td>
</tr>
<tr>
<td>Carmel Buckley</td>
<td>Representing the Office of Nursing &amp; Midwifery Services</td>
</tr>
<tr>
<td>Marie Gleeson</td>
<td>Child Heath/ Immunisation Co-ordinator DML</td>
</tr>
<tr>
<td>Dr. Margaret O Sullivan</td>
<td>Specialist in Public Health Medicine, HSE South (Cork and Kerry)</td>
</tr>
<tr>
<td>Carmel Fallon (secretary from March 2012)</td>
<td>Infection Prevention and Control Nurse, Department of Public Health HSE West (Galway, Mayo and Roscommon)</td>
</tr>
<tr>
<td>Ger O Connor</td>
<td>Public Health Nurse, HSE East</td>
</tr>
<tr>
<td>Marianne Healy</td>
<td>Director of Public Health Nursing, HSE East</td>
</tr>
<tr>
<td>Dr. Terry O Connor</td>
<td>representing the Irish Thoracic Society</td>
</tr>
<tr>
<td>Dr. Mary Scully</td>
<td>Specialist in Public Health Medicine, HSE East</td>
</tr>
</tbody>
</table>
Appendix VI: List of Stakeholders Involved in Peer Review

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix VII: DOT Recording Form

<table>
<thead>
<tr>
<th>Patient Surname:</th>
<th>Forename:</th>
<th>DOB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Address

Contact Numbers:

Consultant

<table>
<thead>
<tr>
<th>Medications</th>
<th>Name</th>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please observe above named taking listed medications and sign opposite appropriate date

<table>
<thead>
<tr>
<th>Day</th>
<th>Date and Time Morning (AM)</th>
<th>Date and Time Evening (PM)</th>
<th>Notes</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thursday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saturday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thursday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2 The above form is a sample form and may need to be adapted for local use